MedTrace Logo

Coenzyme Q10 for Neuroprotection in Paclitaxel-Induced Neuropathy

NCT07307911 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-04-08

No results posted yet for this study

Summary

* This study aims to investigate whether Coenzyme Q10 supplementation can reduce chemotherapy-induced peripheral neuropathy, fatigue, and pain in women with newly diagnosed breast cancer receiving paclitaxel treatment. The study will also examine the effects of Coenzyme Q10 on biomarkers associated with nerve damage. The main questions it seeks to answer are:
* Does Coenzyme Q10 improve patients' quality of life by reducing neuropathy, fatigue, and pain during chemotherapy?
* How does Coenzyme Q10 affect serum levels of nerve growth factor, neurofilament light chain, malondialdehyde, and osteopontin during treatment?
* Participants will: Receive either Coenzyme Q10 along with standard weekly paclitaxel chemotherapy or paclitaxel alone for twelve weeks.
* Complete questionnaires on neuropathy, fatigue, and pain at the end of each chemotherapy cycle.
* Provide blood samples at the beginning and end of the study to measure biomarkers of nerve injury.

Conditions

Interventions

DIETARY_SUPPLEMENT

Coenzyme Q 10

Coenzyme Q10 200 mg orally twice daily for twelve weeks, for CoQ 10 grpup only

DRUG

Paclitaxel

: Paclitaxel 80 mg/m² administered weekly for twelve weeks to Control and CoQ groups

Sponsors & Collaborators

  • Damanhour University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-11-10
Primary Completion
2026-02-10
Completion
2026-02-10

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07307911 on ClinicalTrials.gov